HBAN
56
2
AKAM
50
7
MTB
65
2
PPL
59
5
FLR
55
6
HSIC
51
-3
GOOGL
45
-9
PSA
56
5
MLM
51
3
LEN
52
2
MDT
62
3
PPG
60
3
GWW
71
4
GS
73
7
AMAT
42
6
TRV
56
3
LB
41
7
SYY
49
2
ETN
79
4
CMCSA
52
4
HBAN
56
2
AKAM
50
7
MTB
65
2
PPL
59
5
FLR
55
6
HSIC
51
-3
GOOGL
45
-9
PSA
56
5
MLM
51
3
LEN
52
2
MDT
62
3
PPG
60
3
GWW
71
4
GS
73
7
AMAT
42
6
TRV
56
3
LB
41
7
SYY
49
2
ETN
79
4
CMCSA
52
4
Financhill
Back

Beam Therapeutics 10K Form

Buy
52

BEAM
Beam Therapeutics

Last Price:
24.63
Seasonality Move:
42.3%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q BEAM/Beam Therapeutics Quarterly
2023-08-08 10Q BEAM/Beam Therapeutics Quarterly
2023-05-10 10Q BEAM/Beam Therapeutics Quarterly
2022-11-07 10Q BEAM/Beam Therapeutics Quarterly
2022-08-09 10Q BEAM/Beam Therapeutics Quarterly
2022-05-09 10Q BEAM/Beam Therapeutics Quarterly

Receive BEAM News And Ratings

See the #1 stock for the next 7 days that we like better than BEAM

BEAM Financial Statistics

Sales & Book Value

Annual Sales: $377.71M
Cash Flow: $-89.7M
Price / Cash Flow: 0
Annual Sales: $9.58
Price / Book: 2.47

Profitability

EPS (TTM): -1.76000
Net Income (TTM): $-143.59M
Gross Margin: $1.48B
Return on Equity: -16.62%
Return on Assets: -10.97%

Beam Therapeutics Earnings Forecast

Key Beam Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for BEAM is 58.08%.
  • The Selling, General & Administrative Expenses for BEAM have been equal to 30.93% of Gross Profit Margin.
  • The Research & Development expenses have been 115.80% of Revenue.
  • The Interest Expense is -0.24% of Operating Income.
  • The Net Earning history of BEAM is -35.09% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 6 years.

Beam Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BEAM
CUSIP: 07373V
Website: beamtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.69
Quick Ratio: 5.57

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BEAM Technical Analysis vs Fundamental Analysis

Buy
52
Beam Therapeutics (BEAM) is a Buy

Is Beam Therapeutics a Buy or a Sell?

  • Beam Therapeutics stock is rated a Buy
    The current Beam Therapeutics [BEAM] share price is $23.58. The Score for BEAM is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.